Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6415MR)

This product GTTS-WQ6415MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6415MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2897MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ14280MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ496MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ979MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ2388MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ8225MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ6955MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ8337MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW